Minocycline improves peripheral and autonomic neuropathy in type 2 diabetes: MIND
study.
Author(s): Syngle A(1), Verma I, Krishan P, Garg N, Syngle V.
Affiliation(s): Author information:
(1)Healing Touch City Clinic, Chandigarh and Senior Consultant Physician and
Rheumatologist Fortis Multi Specialty Hospital, Mohali, India,
ashitsyngle@yahoo.com.
Publication date & source: 2014, Neurol Sci. , 35(7):1067-73
Diabetic peripheral neuropathy and diabetic autonomic neuropathy are serious and
common complications of diabetes associated with increased risk of mortality and
cardiovascular disease. We sought to evaluate the safety and efficacy of
minocycline in type 2 diabetic patients with diabetic peripheral and autonomic
neuropathy. In a randomized placebo controlled study, 50 outpatients were
randomly assigned to receive 100 mg minocycline or placebo. Outcome measures
included the vibration perception threshold (VPT), Leeds assessment of
neuropathic symptoms and signs (LANSS), Pain Disability Index (PDI), Visual
Analog Scale (VAS), beck depression inventory (BDI), health assessment
questionnaire (HAQ) and autonomic neuropathy, assessed by cardiovascular reflex
tests according to Ewing and peripheral sympathetic autonomic function was
assessed by FDA approved Sudoscan. At baseline there were no significant
differences between demographic variables and the neuropathy variables in the
minocycline and placebo groups. After treatment, VPT significantly improved in
the minocycline group as compared to the placebo group. Mean posttreatment scores
on the LANSS, PDI and HAQ were significantly lower in the minocycline group
compared with the placebo group. However, BDI and VAS significantly (p = 0.01)
improved in both minocycline and placebo groups (Table 2). After treatment with
minocycline, heart rate (HR) response to standing significantly improved, while
there was a borderline significance toward a reduction in HR response to deep
breath. These finding indicate that 6-week oral treatment with minocycline is
safe, well tolerated and significantly improves peripheral and autonomic
neuropathy in type 2 diabetic patients.
|